
According to Benzinga Pro data, during Q4, Revance Therapeutics (NASDAQ:RVNC) posted sales of $25.95 million. Earnings were up 15.16%, but Revance Therapeutics still reported an overall loss of $63.10 million. In Q3, Revance Therapeutics brought in $19.75 million in sales but lost $74.38 million in earnings.